History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies considered cured and not expected to require active therapy (for example, certain skin cancers or in situ malignancies) per protocol.

Known active leptomeningeal disease or uncontrolled central nervous system metastases.

Active, clinically significant, autoimmune diseases requiring systemic immunosuppressive therapy.

Prior allogenic organ transplantation

Clinically significant uncontrolled medical or psychiatric condition, that in the opinion of the investigator, would increase risk or interfere with trial participation.

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

What this study is about